Search: WFRF:(Atoria Swartz Coral)
> (2014) >
Empirical estimates...
-
Vickers, Andrew J.
(author)
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
- Article/chapterEnglish2014
Publisher, publication year, extent ...
-
2014-02-11
-
Springer Science and Business Media LLC,2014
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:323b67c4-a505-45cf-ad4e-48df40436b20
-
https://lup.lub.lu.se/record/4439428URI
-
https://doi.org/10.1186/1741-7015-12-26DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Background: Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA. Methods: Estimates of the effects of age on overdiagnosis were based on population based incidence data from the US Surveillance, Epidemiology and End Results database. To investigate the relationship between PSA and overdiagnosis, we used two separate cohorts subject to PSA testing in clinical trials (n = 1,577 and n = 1,197) and a population-based cohort of Swedish men not subject to PSA-screening followed for 25 years (n = 1,162). Results: If PSA testing had been restricted to younger men, the number of excess cases associated with the introduction of PSA in the US would have been reduced by 85%, 68% and 42% for age cut-offs of 60, 65 and 70, respectively. The risk that a man with screen-detected cancer at age 60 would not subsequently lead to prostate cancer morbidity or mortality decreased exponentially as PSA approached conventional biopsy thresholds. For PSAs below 1 ng/ml, the risk of a positive biopsy is 65 (95% CI 18.2, 72.9) times greater than subsequent prostate cancer mortality. Conclusions: Prostate cancer overdiagnosis has a strong relationship to age and PSA level. Restricting screening in men over 60 to those with PSA above median (>1 ng/ml) and screening men over 70 only in selected circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sjoberg, Daniel D.
(author)
-
Ulmert, DavidLund University,Lunds universitet,Urologi, Malmö (Abrahamsson),Forskargrupper vid Lunds universitet,Klinisk kemi, Malmö,Urological research, Malmö,Lund University Research Groups,Clinical Chemistry, Malmö(Swepub:lu)klke-dul
(author)
-
Vertosick, Emily
(author)
-
Roobol, Monique J.
(author)
-
Thompson, Ian
(author)
-
Heijnsdijk, Eveline A. M.
(author)
-
De Koning, Harry
(author)
-
Atoria-Swartz, Coral
(author)
-
Scardino, Peter T.
(author)
-
Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-hli
(author)
-
Urologi, Malmö (Abrahamsson)Forskargrupper vid Lunds universitet
(creator_code:org_t)
Related titles
-
In:BMC Medicine: Springer Science and Business Media LLC121741-7015
Internet link
Find in a library
To the university's database
- By the author/editor
-
Vickers, Andrew ...
-
Sjoberg, Daniel ...
-
Ulmert, David
-
Vertosick, Emily
-
Roobol, Monique ...
-
Thompson, Ian
-
show more...
-
Heijnsdijk, Evel ...
-
De Koning, Harry
-
Atoria-Swartz, C ...
-
Scardino, Peter ...
-
Lilja, Hans
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Medicinal Chemis ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Urology and Neph ...
- Articles in the publication
-
BMC Medicine
- By the university
-
Lund University